The Hormone Therapy That 6,000 Prostate Cancer Patients Helped Prove Most Men Don't Need

Testosterone: the molecule your body uses to build muscle, deepen voices, and - occasionally - fuel prostate cancer cells that didn't get the memo about behaving themselves after surgery. For years, doctors treating men whose prostate cancer came back after surgery faced a nagging question: when you fire up the radiation cannon at the surgical site, should you also slam the brakes on testosterone? A massive new study just answered that question, and the short version is: for most guys, probably not.

The Setup: Surgery, Then "Uh Oh"

Prostate cancer is the single most commonly diagnosed cancer in men across 118 countries, with roughly 1.5 million new cases per year globally (Sung et al., 2021). Radical prostatectomy - removing the whole prostate - works well for many, but somewhere between 20% and 50% of patients see their PSA levels creep back up afterward, a biochemical red flag that cancer cells are still lurking. The standard rescue play? Salvage radiation therapy aimed at the prostate bed. And for the last two decades, doctors have increasingly tacked on androgen deprivation therapy (ADT) - essentially a chemical testosterone shutdown - hoping the one-two punch would keep cancer from coming back for good.

The problem? ADT is not exactly a walk in the park. Think hot flashes that make menopause look like a mild inconvenience, bone density loss, fatigue that could flatten a marathon runner, muscle wasting, sexual dysfunction, and cognitive fog. If you're going to put someone through all that, you'd better be sure it's actually helping.

POSEIDON Rises From the Data

Enter the POSEIDON meta-analysis, a tour-de-force collaboration from the MARCAP Consortium that pooled individual patient data from six randomized Phase III trials - including heavyweights like RTOG 9601, GETUG-AFU 16, RADICALS-HD, and SPPORT - totaling 6,057 patients with a median follow-up of nine years (Kishan et al., 2026). That's not a study; that's a census.

The headline finding: adding hormone therapy to postoperative radiation did not significantly improve overall survival (hazard ratio 0.87, p = 0.06). After 10 years, 84.3% of men who got hormones plus radiation were alive compared to 83.6% who got radiation alone. That's a 0.7% absolute difference - roughly the margin by which your favorite sports team wins a coin toss.

The PSA Plot Twist

But here's where it gets interesting. When the researchers sliced the data by PSA levels at the time of radiation, a clear pattern emerged. Men with a PSA of 0.5 ng/mL or lower - the majority of patients getting early salvage radiation - saw zero survival benefit from the added hormones. They went through the hot flashes, the fatigue, the whole hormonal rollercoaster, for essentially nothing.

Men with PSA above 0.5 ng/mL, however, did show meaningful improvement. And for those who do need it? Short-term therapy (4 to 6 months) appears to work just as well as the 24-month marathon regimen that's been standard in many clinics. As lead author Dr. Amar Kishan of UCLA put it: for most patients, short-term hormone therapy will suffice.

What Your Oncologist Is Thinking Right Now

In their Lancet commentary on the study, Aparicio and Pilié emphasize the clinical significance of these findings (Aparicio & Pilié, 2026). The takeaway isn't that hormone therapy is useless - it's that the medical community has been applying it too broadly. Not every man receiving salvage radiation needs his testosterone levels cratered into oblivion.

This is precision medicine in action: stop treating everyone the same and start figuring out who actually benefits. The next frontier involves developing biomarkers - genomic tests like PAM50 are already showing promise in related trials (Spratt et al., 2025) - that can predict which patients truly need hormone therapy layered onto their radiation.

The Bottom Line

For the thousands of men diagnosed with recurrent prostate cancer each year, this study is genuinely good news. If your PSA is low when you start salvage radiation, you can likely skip the hormones and spare yourself months of side effects that nobody signed up for. If your PSA is higher, a shorter course of ADT appears to do the job. Either way, the days of reflexively adding hormone therapy to every salvage radiation prescription appear to be numbered.

Cancer treatment is slowly but surely learning a lesson the rest of us figured out about hot sauce long ago: more is not always better.

References

1. Kishan AU, et al. Hormone therapy use and duration with postoperative radiotherapy for recurrent prostate cancer: an individual patient data meta-analysis. Lancet. 2026. DOI: 10.1016/S0140-6736(26)00137-6. PMID: 41765025

2. Aparicio AM, Pilié PG. Impact of adding hormone therapy to postoperative radiotherapy in prostate cancer. Lancet. 2026. DOI: 10.1016/S0140-6736(26)00368-5. PMID: 41765028

3. Carrie C, et al. Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial. Lancet Oncol. 2019;20(12):1740-1749. DOI: 10.1016/S1470-2045(19)30486-3. PMID: 31629656

4. Sung H, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. DOI: 10.3322/caac.21660. PMID: 33538338

5. Kishan AU, et al. Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis. Lancet Oncol. 2022;23(2):304-316. DOI: 10.1016/S1470-2045(21)00705-1. PMID: 35051385

Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.